Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study

Mov Disord. 1994 Jul;9(4):431-6. doi: 10.1002/mds.870090409.


We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single-blind, crossover study. Patients were placed randomly on the sequence bromocriptine-pergolide (12 + 12 weeks) or vice versa. Regular evaluations using the New York University Parkinson's Disease Scale were performed by a clinician blinded to treatment assignment. Patients' and clinicians' impressions also were recorded. The average daily dose of pergolide was 2.3 +/0- 0.8 mg, and that of bromocriptine was 24.2 +/- 8.4 mg. Significantly greater efficacy was demonstrated by both drugs as adjunctive therapy to levodopa compared with previous treatment of levodopa alone (pergolide, p = 0.0001; bromocriptine, p = 0.0005; Wilcoxon t test). Pergolide was more effective than bromocriptine in daily living scores (p = 0.020) and motor scores (p = 0.038). No difference in dyskinesias, dystonias, and psychosis was observed. Adverse events were more frequent in bromocriptine-treated patients. Most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bromocriptine / adverse effects
  • Bromocriptine / therapeutic use*
  • Cross-Over Studies
  • Disability Evaluation
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Humans
  • Infant
  • Levodopa / adverse effects
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Neurologic Examination / drug effects
  • Parkinson Disease / drug therapy*
  • Pergolide / adverse effects
  • Pergolide / therapeutic use*
  • Single-Blind Method
  • Treatment Outcome


  • Pergolide
  • Bromocriptine
  • Levodopa